Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression

• Published in: Progress in neuro-psychopharmacology & biological psychiatry 2006-03, Vol.30 (2), p.306-309
• Main Authors: Wang, Tzong-Shi, Chou, Yuan-Hwa, Shiah, I-Shin
• Format: Article
• Language: English
• Subjects: Adult; Adult and adolescent clinical studies; Anorexia nervosa; Anorexia Nervosa - complications; Anorexia Nervosa - drug therapy; Antidepressive Agents, Tricyclic - therapeutic use; Antiemetics - therapeutic use; Benzodiazepines - therapeutic use; Biological and medical sciences; Depression; Depressive Disorder, Major - complications; Depressive Disorder, Major - drug therapy; Drug Therapy, Combination; Eating behavior disorders; Female; Humans; Major depression; Medical sciences; Mianserin - analogs & derivatives; Mianserin - therapeutic use; Mirtazapine; Mood disorders; Neuropharmacology; Olanzapine; Pharmacology. Drug treatments; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology
• ISSN: 0278-5846; 1878-4216
• DOI: 10.1016/j.pnpbp.2005.10.004

Several studies have shown that olanzapine is effective in weight restoration and maintenance for patients with anorexia nervosa (AN). However, major depression is a very common comorbid psychiatric disorder associated with AN. Additional antidepressant therapy may be required for treating anorexic patients with major depression. The authors present a case of AN associated with major depression, who responded well to the combination treatment of olanzapine and mirtazapine. A 27-year-old Taiwanese woman was admitted because of severe weight loss, poor nutrition, amenorrhea, major depression, and starvation complications including hematological dyscrasis, electrolytes and endocrine imbalance, and sinus bradycardia. In additional to nutritional and medical treatments, the patient was given olanzapine 10 mg/day and mirtazapine 30 mg/day. She took the combined medications for six months. Meanwhile she received cognitive behavior therapy and family therapy. With these treatments, the patient's depression was in remission, her body weight was increased from 24 to 38 kg, and her body mass index was increased from 9.8 to 15.5. Our case suggests that the combined treatment of olanzapine and mirtazapine can be used in the treatment of AN associated with major depression.